These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33247603)

  • 1. Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Güttler C; Altschüler J; Tanev K; Böckmann S; Haumesser JK; Nikulin VV; Kühn AA; van Riesen C
    Mov Disord; 2021 Apr; 36(4):927-937. PubMed ID: 33247603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Baufreton J; Milekovic T; Li Q; McGuire S; Moraud EM; Porras G; Sun S; Ko WKD; Chazalon M; Morin S; Normand E; Farjot G; Milet A; Pype J; Pioli E; Courtine G; Bessière B; Bezard E
    Mov Disord; 2018 Oct; 33(10):1632-1642. PubMed ID: 29756234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
    Konitsiotis S; Tsironis C
    Behav Brain Res; 2006 Jun; 170(2):337-41. PubMed ID: 16621050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
    Steece-Collier K; Stancati JA; Collier NJ; Sandoval IM; Mercado NM; Sortwell CE; Collier TJ; Manfredsson FP
    Mov Disord; 2019 May; 34(5):697-707. PubMed ID: 31002755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
    Bi Y; Wang P; Yu J; Wang Z; Yang H; Deng Y; Guan J; Zhang W
    CNS Neurosci Ther; 2023 Oct; 29(10):2998-3013. PubMed ID: 37122156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
    Dupre KB; Cruz AV; McCoy AJ; Delaville C; Gerber CM; Eyring KW; Walters JR
    Neurobiol Dis; 2016 Feb; 86():1-15. PubMed ID: 26586558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of deep brain stimulation on levodopa-induced dyskinesias and striatal oscillatory local field potentials in a rat model of Parkinson's disease.
    Alam M; Capelle HH; Schwabe K; Krauss JK
    Brain Stimul; 2014; 7(1):13-20. PubMed ID: 24126192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
    Jin X; Schwabe K; Krauss JK; Alam M
    Exp Brain Res; 2016 Apr; 234(4):1105-18. PubMed ID: 26724931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
    Iyer V; Venkiteswaran K; Savaliya S; Lieu CA; Handly E; Gilmour TP; Kunselman AR; Subramanian T
    Neurobiol Dis; 2021 Nov; 159():105491. PubMed ID: 34461264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finely-tuned gamma oscillations: Spectral characteristics and links to dyskinesia.
    Wiest C; Torrecillos F; Tinkhauser G; Pogosyan A; Morgante F; Pereira EA; Tan H
    Exp Neurol; 2022 May; 351():113999. PubMed ID: 35143832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.